Status:
COMPLETED
Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO
Lead Sponsor:
Central Hospital, Nancy, France
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Shock, Cardiogenic
Extra-Corporeal-Life-Support ( ECLS)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Refractory cardiogenic shock is characterized by a decreased in cardiac output with hypo-responsiveness to increasing doses of catecholamines resulting in a profound tissular ischemia. VAECMO, by rest...
Detailed Description
NB : A repartition according to other ongoing study (HYPOECMO NCTNCT02754193) is planned
Eligibility Criteria
Inclusion
- Patients in ICU
- Refractory cardiogenic shock
- Cardiogenic shock: Systolic Arterial Pressure \<90mmHg, or Mean Arterial Pressure \<65mmHg, adequate volemia, peripheral hypoperfusion symptoms, cardiac index \< 2.2 l/min/m2)
- Refractory state: hypo responsiveness to norepinephrine AND/OR persisting profound hypo perfusion clinical symptoms despite optimal resuscitation
- needing an Extra-Corporeal-Life-Support
- informed consent from relatives or patient
- Affiliation to a social security regimen
- Preliminary medical examination
Exclusion
- Patients under ECLS for a/an :
- Cardiotoxic poisoning
- Human immunodeficient Virus or Viral hepatitis C
- Patient \< 18 yo
- Pregnancy
- Patient under protective supervision
Key Trial Info
Start Date :
October 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 24 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT03327493
Start Date
October 10 2017
End Date
May 24 2022
Last Update
April 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Nancy
Nancy, France, 54000